The scleroderma therapeutics market has gained significant traction in recent years, driven by an increase in the prevalence of scleroderma and heightened global awareness about the disease. With the market's value standing at USD 2.04 billion in 2023, experts anticipate robust growth, projecting a Compound Annual Growth Rate (CAGR) of 6.20% during the forecast period from 2024 to 2032. By...